Lisheng Pharmaceutical Flags Sharp Decline in H1 Profit
() -- Tianjin Lisheng Pharmaceutical (SHE:002393) expects attributable net profit of 730 million yuan to 830 million yuan for the first half of 2026, down 76% to 79% from 3.43 billion yuan in the year-earlier period, according to a Wednesday Hong Kong bourse filing by parent Tianjin Development (HKG:0882). Basic earnin